Journal
EUROPEAN JOURNAL OF PHARMACOLOGY
Volume 884, Issue -, Pages -Publisher
ELSEVIER
DOI: 10.1016/j.ejphar.2020.173446
Keywords
Ambroxol; ALS; Neurodegenerative disease; GBA2; Glucosylceramide
Categories
Funding
- Association pour la recherche et le developpement de moyens de lutte contre les maladies neurodegeneratives
- FightMND (Australia)
- FightMND Mid-Career Research Fellowship
Ask authors/readers for more resources
Amyotrophic lateral sclerosis (ALS) is the most common motor neuron disease in adults. While it is primarily characterized by the death of upper and lower motor neurons, there is a significant metabolic component involved in the progression of the disease. Two-thirds of ALS patients have metabolic alterations that are associated with the severity of symptoms. In ALS, as in other neurodegenerative diseases, the metabolism of glycosphingolipids, a class of complex lipids, is strongly dysregulated. We therefore assume that this pathway constitutes an interesting avenue for therapeutic approaches. We have shown that the glucosylceramide degrading enzyme, glucocerebrosidase (GBA) 2 is abnormally increased in the spinal cord of the SOD1(G86R) mouse model of ALS. Ambroxol, a chaperone molecule that inhibits GBA2, has been shown to have beneficial effects by slowing the development of the disease in SOD1(G86R) mice. Currently used in clinical trials for Parkinson's and Gaucher disease, ambroxol could be considered as a promising therapeutic treatment for ALS.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available